Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.

Lee X Li Federico Cappuzzo Ignacio Matos Mark A SocinskiAshley M HopkinsMichael J Sorich

Published in: The oncologist (2023)

This study presents first evidence for a markedly lower hyperprogression risk in advanced NSCLC patients treated with first-line ICI, particularly with chemoimmunotherapy, as compared to second- or later-line ICI treatment.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
clinical trial
phase ii
replacement therapy
brain metastases